ACRS insider trading
Aclaris Therapeutics, Inc. — open-market insider buys and $1M+ sells from SEC Forms 3, 4 and 5.
Buys · last 90 days
0 · $0
Most recent buy
2024-11-20
Recent insider filings
| Filed | Insider | Type | Shares | Price | Value |
|---|
| 2026-04-27 | Leonard Braden Michael 10% owner | Sold | 300,000 | $4.53 | $1.4M |
| 2024-11-20 | Mehra Anand Director | Bought | 666,666 | $2.25 | $1.5M |
Most active insider buyers
| Insider | Role | Buys | Total bought |
|---|
| Mehra Anand | Director | 1 | $1.5M |
See ACRS on the chart
Every insider buy and sell for ACRS plotted on the price, the full two-year history, cluster scores and daily updates — in the members area, $29/month. A free quarterly sample of the whole dataset needs no account.
Open the browserFree sampleData from the SEC EDGAR ownership filings, refreshed daily. Only open-market purchases (transaction code P) and sales of $1M or more are shown; grants, option exercises and tax withholding are excluded because they run on schedules set years earlier. Not investment advice.